IdentificationGeneric Name(1S,2S,3R,6R)-4-(hydroxymethyl)-6-(octylamino)cyclohex-4-ene-1,2,3-triolDrugBank Accession NumberDB08321BackgroundNot AvailableTypeSmall MoleculeGroupsExperimentalStructure


3DDownload MOLSDF3D-SDFPDBSMILESInChI


 Similar StructuresStructure for (1S,2S,3R,6R)-4-(hydroxymethyl)-6-(octylamino)cyclohex-4-ene-1,2,3-triol (DB08321)× CloseWeightAverage: 287.3951 Monoisotopic: 287.209658421 Chemical FormulaC15H29NO4SynonymsNot AvailablePharmacologyIndicationNot AvailableReduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, & validate predictive machine-learning models with structured datasets.See howContraindications & Blackbox WarningsAvoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Learn more  Avoid life-threatening adverse drug events & improve clinical decision support.Learn morePharmacodynamicsNot AvailableMechanism of actionTargetActionsOrganismUAlpha-mannosidase 2Not AvailableHumansAbsorptionNot AvailableVolume of distributionNot AvailableProtein bindingNot AvailableMetabolismNot AvailableRoute of eliminationNot AvailableHalf-lifeNot AvailableClearanceNot AvailableAdverse EffectsImprove decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Learn more  Improve decision support & research outcomes with our structured adverse effects data.Learn moreToxicityNot AvailablePathwaysNot AvailablePharmacogenomic Effects/ADRs 


Not AvailableInteractionsDrug Interactions 


This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist. Not AvailableFood InteractionsNot AvailableCategoriesDrug CategoriesNot AvailableChemical TaxonomyProvided by ClassyfireDescriptionThis compound belongs to the class of organic compounds known as cyclitols and derivatives. These are compounds containing a cycloalkane moiety with one hydroxyl group on each of three or more ring atoms. These of also include derivatives where the hydrogen atom of one or more of the hydroxyl groups is replaced with another atom.KingdomOrganic compoundsSuper ClassOrganic oxygen compoundsClassOrganooxygen compoundsSub ClassAlcohols and polyolsDirect ParentCyclitols and derivativesAlternative ParentsSecondary alcohols / Polyols / Dialkylamines / Primary alcohols / Organopnictogen compounds / Hydrocarbon derivativesSubstituentsAliphatic homomonocyclic compound / Amine / Cyclitol or derivatives / Hydrocarbon derivative / Organic nitrogen compound / Organonitrogen compound / Organopnictogen compound / Polyol / Primary alcohol / Secondary alcoholMolecular FrameworkAliphatic homomonocyclic compoundsExternal DescriptorsNot AvailableAffected organismsNot AvailableChemical IdentifiersUNIINot AvailableCAS numberNot AvailableInChI KeyUPZUHYMBTUUPML-KBXIAJHMSA-NInChIInChI=1S/C15H29NO4/c1-2-3-4-5-6-7-8-16-12-9-11(10-17)13(18)15(20)14(12)19/h9,12-20H,2-8,10H2,1H3/t12-,13-,14+,15+/m1/s1IUPAC Name(1S,2S,3R,6R)-4-(hydroxymethyl)-6-(octylamino)cyclohex-4-ene-1,2,3-triolSMILES[H][C@@]1(O)C(CO)=C[C@@]([H])(NCCCCCCCC)[C@]([H])(O)[C@@]1([H])OReferencesGeneral ReferencesNot AvailableExternal LinksPubChem Compound9817381PubChem Substance99444792ChemSpider7993131BindingDB50358322ChEMBLCHEMBL1234952ZINCZINC000014175217PDBe LigandOEVPDB Entries3d50Clinical TrialsClinical Trials 


PhaseStatusPurposeConditionsCountPharmacoeconomicsManufacturersNot AvailablePackagersNot AvailableDosage FormsNot AvailablePricesNot AvailablePatentsNot AvailablePropertiesStateSolidExperimental PropertiesNot AvailablePredicted PropertiesPropertyValueSourceWater Solubility11.3 mg/mLALOGPSlogP0.95ALOGPSlogP0.4ChemaxonlogS-1.4ALOGPSpKa (Strongest Acidic)12.83ChemaxonpKa (Strongest Basic)8.47ChemaxonPhysiological Charge1ChemaxonHydrogen Acceptor Count5ChemaxonHydrogen Donor Count5ChemaxonPolar Surface Area92.95 Å2ChemaxonRotatable Bond Count9ChemaxonRefractivity78.94 m3·mol-1ChemaxonPolarizability33.59 Å3ChemaxonNumber of Rings1ChemaxonBioavailability1ChemaxonRule of FiveYesChemaxonGhose FilterYesChemaxonVeber's RuleNoChemaxonMDDR-like RuleNoChemaxonPredicted ADMET FeaturesPropertyValueProbabilityHuman Intestinal Absorption+0.9482Blood Brain Barrier-0.9787Caco-2 permeable-0.6232P-glycoprotein substrateSubstrate0.7566P-glycoprotein inhibitor INon-inhibitor0.8102P-glycoprotein inhibitor IINon-inhibitor0.6793Renal organic cation transporterNon-inhibitor0.825CYP450 2C9 substrateNon-substrate0.81CYP450 2D6 substrateNon-substrate0.6983CYP450 3A4 substrateNon-substrate0.578CYP450 1A2 substrateNon-inhibitor0.7367CYP450 2C9 inhibitorNon-inhibitor0.8951CYP450 2D6 inhibitorNon-inhibitor0.744CYP450 2C19 inhibitorNon-inhibitor0.898CYP450 3A4 inhibitorNon-inhibitor0.9826CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9125Ames testNon AMES toxic0.8035CarcinogenicityNon-carcinogens0.9477BiodegradationReady biodegradable0.6596Rat acute toxicity2.0258 LD50, mol/kg Not applicablehERG inhibition (predictor I)Weak inhibitor0.6589hERG inhibition (predictor II)Non-inhibitor0.748  ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397) SpectraMass Spec (NIST)Not AvailableSpectraSpectrumSpectrum TypeSplash KeyPredicted GC-MS Spectrum - GC-MSPredicted GC-MSNot AvailablePredicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot AvailablePredicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot AvailablePredicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot AvailablePredicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot AvailablePredicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot AvailablePredicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot AvailableTargetsBuild, predict & validate machine-learning modelsUse our structured and evidence-based datasets to unlock newinsights and accelerate drug research.Learn more  Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.Learn more


 Details1. Alpha-mannosidase 2KindProteinOrganismHumansPharmacological actionUnknownGeneral FunctionZinc ion bindingSpecific FunctionCatalyzes the first committed step in the biosynthesis of complex N-glycans. It controls conversion of high mannose to complex N-glycans; the final hydrolytic step in the N-glycan maturation pathway.Gene NameMAN2A1Uniprot IDQ16706Uniprot NameAlpha-mannosidase 2Molecular Weight131139.485 DaReferencesBerman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [Article] ×Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice. Learn more   Drug created at September 15, 2010 21:30 / Updated at June 12, 2020 16:52 